|
Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes Clinical research trials and Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes. Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes clinical trial. Subjects often receive the most expert healthcare possible for their Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes  Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes
Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes
For Condition: Diabetic Nephropathy,Diabetes Mellitus
Status: Recruiting
Sponsor(s): Sharma, Kumar, M.D. , National Institutes of Health (NIH),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),InterMune
Synopsis: The purpose of this study is to determine whether a new investigational drug, pirfenidone, will be an effective therapy for diabetic patients with kidney dysfunction. Our hypothesis is that administration of pirfenidone to type 1 and type 2 diabetic patients with advanced kidney disease will lead to preservation of kidney function.
Details: Diabetic kidney disease is the leading cause of new cases of kidney failure in the United States. In the kidneys of diabetic patients, there is accumulation of protein that leads to the formation of scar tissue and poor kidney function. Because of this many patients eventually require dialysis or kidney transplantation. A new investigational drug, pirfenidone, has been shown to be beneficial in a number of diseases in which scar formation leads to disease progression. It is our goal to examine whether pirfenidone is effective at stabilizing or reducing progressive diabetic kidney dysfunction.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion - Type 1 or type 2 diabetes - Males and females greater than or equal to 18 years. - Abnormal kidney function determined by glomerular filtration rate - History of proteinuria - Blood pressure controlled to <140/90 on anti-hypertensive medication Exclusion - Cancer, liver disease, hepatitis, HIV+ - History of heart attack, unstable angina, stroke or peptic ulcer in the past 6 months - Pregnant or planning to become pregnant during the study period - Other known kidney disease besides diabetic nephropathy - Expect to begin dialysis or receive a kidney transplant within 1 year of study enrollment
Total Enrollment: 120
Location and Contact Information:
The Center for Diabetic Kidney Disease at Thomas Jefferson University *Recruiting*
Philadelphia, Pennsylvania, 19107
United States
Recruiting Barbara Francos 215-503-3000
Additional Information:
Study ID Numbers: 1-RO1-DK63017-01;
Study Start Date: June 2003
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063583
Other Diabetic Nephropathy Studies:
1. Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes
2. Treatment of Diabetic Nephropathy
3. Soy Protein in Early Diabetic Nephropathy
4. The effect of LY333531 on protein in the urine in patients with type 2 diabetes.
5. Study of Drugs for High Blood Pressure and High Cholesterol in American Indians with Type 2 Diabetes at High Risk of Kidney or Heart Disease
Related Studies:
Other Diabetic Nephropathy Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes
|
|
|
|
|
|
|
|
